CN110267989A - 抗cd40抗体、其抗原结合片段及其医药用途 - Google Patents

抗cd40抗体、其抗原结合片段及其医药用途 Download PDF

Info

Publication number
CN110267989A
CN110267989A CN201880010464.7A CN201880010464A CN110267989A CN 110267989 A CN110267989 A CN 110267989A CN 201880010464 A CN201880010464 A CN 201880010464A CN 110267989 A CN110267989 A CN 110267989A
Authority
CN
China
Prior art keywords
seq
antibody
sequence
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880010464.7A
Other languages
English (en)
Other versions
CN110267989B (zh
Inventor
闫树德
蒋家骅
胡齐悦
张连山
曹国庆
钱雪明
滕菲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN110267989A publication Critical patent/CN110267989A/zh
Application granted granted Critical
Publication of CN110267989B publication Critical patent/CN110267989B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas

Abstract

提供了抗CD40抗体、其抗原结合片段及其医药用途。进一步地，提供了包含所述抗CD40抗体CDR区的嵌合抗体、人源化抗体，以及包含人抗CD40抗体及其抗原结合片段的药物组合物，以及其作为抗癌药物的用途。尤其地，提供了一种人源化的抗CD40抗体，在制备用于治疗CD40介导的疾病或病症的药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (26)

  1. PCT国内申请，权利要求书已公开。
CN201880010464.7A 2017-06-01 2018-05-31 抗cd40抗体、其抗原结合片段及其医药用途 Active CN110267989B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017104025590 2017-06-01
CN201710402559 2017-06-01
PCT/CN2018/089252 WO2018219327A1 (zh) 2017-06-01 2018-05-31 抗cd40抗体、其抗原结合片段及其医药用途

Publications (2)

Publication Number Publication Date
CN110267989A true CN110267989A (zh) 2019-09-20
CN110267989B CN110267989B (zh) 2023-04-04

Family

ID=64454385

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880010464.7A Active CN110267989B (zh) 2017-06-01 2018-05-31 抗cd40抗体、其抗原结合片段及其医药用途

Country Status (11)

Country Link
US (1) US11525005B2 (zh)
EP (1) EP3632932A4 (zh)
JP (1) JP7257971B6 (zh)
KR (1) KR20200012920A (zh)
CN (1) CN110267989B (zh)
AU (1) AU2018278051A1 (zh)
BR (1) BR112019025048A2 (zh)
CA (1) CA3064298A1 (zh)
MX (1) MX2019014375A (zh)
TW (1) TWI699376B (zh)
WO (1) WO2018219327A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112839961A (zh) * 2018-11-30 2021-05-25 江苏恒瑞医药股份有限公司 一种cd40抗体药物组合物及其用途
WO2022247905A1 (zh) * 2021-05-26 2022-12-01 安徽瀚海博兴生物技术有限公司 抗cd40抗体及其用途

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3120793A1 (en) * 2018-11-30 2020-06-04 Jiangsu Hengrui Medicine Co., Ltd. Anti-cd40 antibody, antigen binding fragment and pharmaceutical use thereof
WO2020253722A1 (en) * 2019-06-17 2020-12-24 Eucure (Beijing) Biopharma Co., Ltd Anti-cd40 antibodies and uses thereof
TW202144421A (zh) * 2020-03-30 2021-12-01 大陸商正大天晴藥業集團股份有限公司 結合cd40的抗體及其用途
CA3232171A1 (en) * 2021-09-24 2023-03-30 Zhenzhen Lu Anti-cd40 antibody and use thereof
CN114573698B (zh) * 2022-03-16 2023-01-06 沈阳三生制药有限责任公司 一种FcRn抗原结合蛋白及其制备方法和应用
TW202340256A (zh) * 2022-04-02 2023-10-16 大陸商和鉑醫藥（上海）有限責任公司 一種標靶ｃｄ４０的抗原結合蛋白及其製備和應用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1582165A (zh) * 2001-11-09 2005-02-16 辉瑞产品公司 Cd40的抗体
CA2544949A1 (en) * 2003-11-04 2005-05-19 Chiron Corporation Antagonist anti-cd40 monoclonal antibodies and methods for their use
CN101508734A (zh) * 2001-04-27 2009-08-19 协和发酵麒麟株式会社 抗cd40单克隆抗体
CN102448989A (zh) * 2009-03-10 2012-05-09 贝勒研究院 抗-cd40抗体及其用途
CN102918063A (zh) * 2010-03-31 2013-02-06 贝林格尔.英格海姆国际有限公司 抗-cd40抗体
CN104918957A (zh) * 2012-10-30 2015-09-16 埃派斯进有限公司 抗-cd40抗体及其使用方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10308991A (ja) 1997-05-07 1998-11-17 Mitsubishi Electric Corp スピーカー取付構造
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US20030059427A1 (en) 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
DE60143535D1 (de) 2000-10-02 2011-01-05 Novartis Vaccines & Diagnostic Humane antikörper gegen cd40
US8277810B2 (en) * 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
WO2006073443A2 (en) 2004-04-27 2006-07-13 Novartis Vaccines And Diagnostics, Inc. Antagonist anti-cd40 monoclonal antibodies and methods for their use
WO2006006468A1 (ja) * 2004-07-08 2006-01-19 Uchiyama Manufacturing Corp. フッ素ゴム組成物
BRPI0610470A2 (pt) 2005-05-26 2010-06-22 Seattle Genetics Inc anticorpo isolado ou fragmento de ligação a antìgeno que especificamente se liga a cd40 humano, kit, composição farmacêutica, e, polinucleotìdeo isolado
EP1854810A1 (en) 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
MY166429A (en) * 2010-11-17 2018-06-26 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
CN106977604A (zh) * 2011-04-21 2017-07-25 百时美施贵宝公司 拮抗cd40之抗体多肽
MX339239B (es) 2011-04-29 2016-05-18 Apexigen Inc Anticuerpos anti-cd40 y metodos de uso.
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
GB201322583D0 (en) 2013-12-19 2014-02-05 Alligator Bioscience Ab Antibodies
BR112017020952A2 (pt) 2015-04-13 2018-07-10 Five Prime Therapeutics Inc método de tratamento de câncer, composição e uso da composição
CA2987051A1 (en) 2015-05-29 2016-12-08 Abbvie Inc. Anti-cd40 antibodies and uses thereof
US20180142030A1 (en) 2015-06-29 2018-05-24 Bristol-Myers Squibb Company Antibodies to cd40
SI3307322T1 (sl) 2015-09-04 2021-08-31 Primatope Therapeutics Inc. Humanizirana protitelesa proti CD40 in njihove uporabe
CN106957366B (zh) * 2016-01-12 2022-02-01 上海昀怡健康科技发展有限公司 一种C5aR抗体及其制备方法和应用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101508734A (zh) * 2001-04-27 2009-08-19 协和发酵麒麟株式会社 抗cd40单克隆抗体
CN1582165A (zh) * 2001-11-09 2005-02-16 辉瑞产品公司 Cd40的抗体
CA2544949A1 (en) * 2003-11-04 2005-05-19 Chiron Corporation Antagonist anti-cd40 monoclonal antibodies and methods for their use
CN102448989A (zh) * 2009-03-10 2012-05-09 贝勒研究院 抗-cd40抗体及其用途
CN102918063A (zh) * 2010-03-31 2013-02-06 贝林格尔.英格海姆国际有限公司 抗-cd40抗体
CN104918957A (zh) * 2012-10-30 2015-09-16 埃派斯进有限公司 抗-cd40抗体及其使用方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LARSEN C P等: "Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways", 《NATURE》 *
SCHOENBERGER S等: "T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions", 《NATURE》 *
周照华等: "激发型抗CD40单克隆抗体对CD40+B细胞恶性肿瘤的生长抑制和促凋亡作用", 《中华血液学杂志》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112839961A (zh) * 2018-11-30 2021-05-25 江苏恒瑞医药股份有限公司 一种cd40抗体药物组合物及其用途
CN112839961B (zh) * 2018-11-30 2023-04-04 江苏恒瑞医药股份有限公司 一种cd40抗体药物组合物及其用途
WO2022247905A1 (zh) * 2021-05-26 2022-12-01 安徽瀚海博兴生物技术有限公司 抗cd40抗体及其用途

Also Published As

Publication number Publication date
TWI699376B (zh) 2020-07-21
MX2019014375A (es) 2020-01-23
RU2019141751A (ru) 2021-07-12
RU2019141751A3 (zh) 2021-08-26
JP7257971B6 (ja) 2023-07-24
US11525005B2 (en) 2022-12-13
JP2020521504A (ja) 2020-07-27
KR20200012920A (ko) 2020-02-05
EP3632932A4 (en) 2021-08-18
CN110267989B (zh) 2023-04-04
WO2018219327A1 (zh) 2018-12-06
JP7257971B2 (ja) 2023-04-14
BR112019025048A2 (pt) 2020-06-30
AU2018278051A1 (en) 2020-01-30
CA3064298A1 (en) 2018-12-06
EP3632932A1 (en) 2020-04-08
TW201902925A (zh) 2019-01-16
US20200148778A1 (en) 2020-05-14

Similar Documents

Publication Publication Date Title
JP6983371B2 (ja) 抗ｐｄ−ｌ１抗体、その抗原結合フラグメントおよびその医療用途
CN110267989A (zh) 抗cd40抗体、其抗原结合片段及其医药用途
CN108779179A (zh) Cd47抗体、其抗原结合片段及其医药用途
CN109843927A (zh) 抗b7-h3抗体、其抗原结合片段及其医药用途
JP2017500889A (ja) Ｐｄ−１抗体、その抗原結合性断片及びそれらの医学的使用
CN112969714B (zh) 抗cd40抗体、其抗原结合片段及其医药用途
TWI745670B (zh) 抗cd27抗體、其抗原結合片段及其醫藥用途
WO2021098822A1 (zh) 一种双特异性抗体
TWI685504B (zh) 抗gitr抗體、其抗原結合片段及其醫藥用途
RU2779128C2 (ru) Антитело к cd40, его антигенсвязывающий фрагмент и его медицинское применение
RU2778572C1 (ru) Фармацевтическая композиция на основе антител к cd40 и ее применение
WO2021209066A1 (zh) 特异性抗原结合分子，其制备方法及医药用途
CN115947855A (zh) 抗cd24抗体的制备及其用途
TW202108623A (zh) 抗ｔｒｏｐ－２抗體、其抗原結合片段及其醫藥用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40013344

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant